Table 1.
Baseline characteristics of 316 newly diagnosed intensively treated FLT3-internal tandem duplication (ITD) acute myeloid leukemia (AML).
| Characteristics | Total n = 316 (100%) |
|---|---|
| Age (years) at Diagnosis | |
| Median (IQR) | 57.4 (47.7–67.7) |
| Range | 18.6–81.4 |
| Gender: n (%) | |
| Male | 155 (49.1) |
| Female | 161 (50.9) |
| ECOG at Diagnosis: n (%) | |
| 0–1 | 202 (72.9) |
| ≥ 2 | 75 (27.1) |
| WBC at Diagnosis (× 109/L) | |
| Median (IQR) | 51.5 (21.3–118.1) |
| Range | 0.4–433.0 |
| Tumor Burden: n (%) Extramedullary | |
| Yes | 119 (40.9) |
| No | 172 (59.1) |
| Leukostasis | |
| Yes | 49 (15.8) |
| No | 262 (84.2) |
| LDH | |
| > normal | 280 (92.4) |
| normal | 23 (7.6) |
| Biochemistry: Med (IQR) | |
| Creatinine (µM/L) | 80.5 (64.0–102.0) |
| Albumin (g/L) | 36.0 (32.0–40.0) |
| Fibrinogen (g/L) | 4.0 (2.9–5.3) |
| AML Status: n (%) | |
| de novo | 279 (88.6) |
| Secondary AML a | 36 (11.4) |
| Cytogenetic Risk: n (%) | |
| Favorable | 6 (1.9) |
| Intermediate | 295 (93.4) |
| Normal | 238 (75.3) |
| Different from normal | 57 (18.0) |
| Adverse | 15 (4.7) |
| ELN 2010 Prognosis: n (%) | |
| Favorable | 6 (2.0) |
| Intermediate-1 | 230 (76.4) |
| Intermediate-2 | 50 (16.6) |
| Adverse | 15 (5.0) |
| FLT3 Ratio ITD/wt: n (%) | |
| 3–25% | 34 (24.3) |
| 26–50% | 40 (28.6) |
| > 50% | 66 (47.1) |
| NPM1: n (%) | |
| Mutation | 196 (65.1) |
| No mutation | 105 (34.9) |
| IDH1/2 Mutations: n (%) | |
| IDH1 R132 | 10 (6.7) |
| IDH2 R140 | 7 (4.7) |
| IDH2 R172 | 0 (0.0) |
| No mutation | 132 (88.6) |
ECOG, performance status; WBC, white blood cells; AML, acute myeloid leukemia; ELN, European Leukemia Net; ITD, internal tandem duplication; wt, wild type; Med, median; IQR, interquartile range. a non-de novo AML.